Project Grant R01CA282786
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$538K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $754,766.00 to The University of Texas M.D. Anderson Cancer Center to investigate the role of microbiota and microbial extracellular vesicles in metastatic dormancy in melanoma. The award period runs from November 1, 2024 to October 31, 2027. The University of Texas M.D. Anderson Cancer Center is a prominent academic medical center with extensive...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Texas MD Anderson Cancer Center to conduct research aimed at understanding how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The $453,304 award will fund a 5-year project focused on clarifying the signaling mechanisms by which mutant TP53 activates the...
This Project Grant award for $536,186.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct research on APOBEC3A and its role in tumor evolution and intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC). The award will fund this research project over a 3-year period from Sep 30, 2023 to Sep 29, 2026. As...
This federal Project Grant award of $356,732, provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program), supports research to characterize the role of CCR6+ regulatory T cells (Tregs) in the immunosuppressive tumor microenvironment of pancreatic cancer. The awardee, The Medical College of Wisconsin, Inc., will utilize in vitro assays, in vivo models, bulk sequencing, and single-nucleus RNA sequencing to extensively study how the CCR6-CCL20 signaling axis...
This Project Grant award, titled "A NOVEL IMMUNOTHERAPY FOR PANCREATIC CANCER USING MICRO-RNA-29A," was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to the University of Miami in the amount of $107,948. The award will support research to determine the contribution of the TNFR2-miR-29a axis to CD8 T cell dysfunction in pancreatic ductal adenocarcinoma (PDAC), with the goal of generating durable T-cell mediated anti-tumor activity. The...
The National Cancer Institute awarded a $342,397 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Wayne State University to investigate the relationship between MAIT cells and the microbiome in pancreatic cancer liver metastasis. The project aims to advance understanding of this connection and its potential impact on pancreatic cancer progression. The award period runs from September 30, 2024 to April 28, 2028, and the research will be conducted at Wayne State University in Detroit,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $636,222 to the University of Pittsburgh to conduct research aimed at understanding how certain gut bacteria can modulate the immune system to enhance the efficacy of immune checkpoint inhibitor (ICI) cancer therapies, specifically in melanoma. The key objectives are to: Determine if ICI-associated bacteria can metabolize dietary tryptophan into aryl hydrocarbon receptor (AhR)...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $678,399 to The University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study. The goal is to evaluate whether a prebiotic-enriched diet can enhance the gut microbiome and improve response to immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma. The 5-year study will investigate the...